Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • IN BRIEF

Imaging mutant huntingtin in vivo

  1. Sarah Crunkhorn
    View author publications

    You can also search for this author in PubMed  Google Scholar

The development of therapies targeting the toxic mutant HTT (mHTT) aggregates in Huntington disease (HD) is hampered by the lack of imaging methods to visualize mHTT in the living brain. Here, Bertoglio et al. further characterize their PET imaging radioligand — the small molecule CHDI-180R radiolabelled with 11C ([11C]CHDI-180R) — which displays high affinity and selectivity for mHTT aggregates. In mouse models of HD, [11C]CHDI-180R enabled noninvasive in vivo quantification of brain mHTT during disease development and identified time-, dose-, and region-specific suppression of mHTT in response to therapeutic intervention.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 260 (2022)

doi: https://doi.org/10.1038/d41573-022-00044-y

References

  1. Bertoglio, D. et al. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease. Sci. Transl Med. 14, eabm3682 (2022)

    Article  PubMed  Google Scholar 

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links